ATE377077T1 - Humane gil-19/ae289 proteine und dafür kodierende polynukleotide - Google Patents

Humane gil-19/ae289 proteine und dafür kodierende polynukleotide

Info

Publication number
ATE377077T1
ATE377077T1 AT00928535T AT00928535T ATE377077T1 AT E377077 T1 ATE377077 T1 AT E377077T1 AT 00928535 T AT00928535 T AT 00928535T AT 00928535 T AT00928535 T AT 00928535T AT E377077 T1 ATE377077 T1 AT E377077T1
Authority
AT
Austria
Prior art keywords
proteins
polynucleotides coding
human gil
gil
human
Prior art date
Application number
AT00928535T
Other languages
English (en)
Inventor
Kenneth Jacobs
Lynette Fouser
Vikki Spaulding
Dejun Xuan
Original Assignee
Genetics Inst Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22449618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE377077(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst Llc filed Critical Genetics Inst Llc
Application granted granted Critical
Publication of ATE377077T1 publication Critical patent/ATE377077T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT00928535T 1999-04-28 2000-04-28 Humane gil-19/ae289 proteine und dafür kodierende polynukleotide ATE377077T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13147399P 1999-04-28 1999-04-28

Publications (1)

Publication Number Publication Date
ATE377077T1 true ATE377077T1 (de) 2007-11-15

Family

ID=22449618

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928535T ATE377077T1 (de) 1999-04-28 2000-04-28 Humane gil-19/ae289 proteine und dafür kodierende polynukleotide

Country Status (15)

Country Link
EP (2) EP2357193B1 (de)
JP (2) JP4828703B2 (de)
AT (1) ATE377077T1 (de)
BR (1) BR0010097A (de)
CA (1) CA2367965C (de)
CY (1) CY1107138T1 (de)
DE (1) DE60036937T2 (de)
DK (1) DK1177312T3 (de)
ES (2) ES2295026T3 (de)
HK (2) HK1041021A1 (de)
MX (1) MXPA01010883A (de)
NZ (1) NZ515678A (de)
PT (1) PT1177312E (de)
WO (1) WO2000065027A2 (de)
ZA (1) ZA200109270B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016611A2 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2000024758A1 (en) 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
DK1177312T3 (da) * 1999-04-28 2008-02-25 Genetics Inst Llc Humane GIL-19/AE289-proteiner og polynukleotider kodende derfor
ATE458814T1 (de) 1999-12-03 2010-03-15 Zymogenetics Inc Menschliches zytokinrezeptor
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP2194130A1 (de) * 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Zytokin ZCYT018
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
EP1806404B1 (de) * 2000-07-27 2010-08-18 Wyeth LLC Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine
CA2418950A1 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
WO2002068476A2 (en) * 2001-02-23 2002-09-06 Genetics Institute, Llc Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
CA2439961A1 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
US7033787B2 (en) 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
CA2480163A1 (en) 2002-03-22 2003-10-09 Zymogenetics, Inc. Anti-il-tif antibodies and methods of using in inflammation
ATE475673T1 (de) 2003-03-24 2010-08-15 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP1812476B1 (de) 2004-10-22 2010-07-21 ZymoGenetics, Inc. Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
US8524678B2 (en) 2005-05-31 2013-09-03 The Regents Of The University Of Colorado, A Body Corporate Method for delivering genes
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5536637A (en) 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
JPH09501932A (ja) 1993-08-26 1997-02-25 ジェネティックス・インスティテュート・インコーポレイテッド ヒト・骨形態形成蛋白を用いる神経再生
ES2255059T3 (es) 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
US5679523A (en) 1995-11-16 1997-10-21 The Board Of Trustees Of The Leland Stanford Junior University Method for concurrent disruption of expression of multiple alleles of mammalian genes
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
WO2000024758A1 (en) * 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
DK1177312T3 (da) * 1999-04-28 2008-02-25 Genetics Inst Llc Humane GIL-19/AE289-proteiner og polynukleotider kodende derfor
WO2000073457A1 (en) * 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
US20020187512A1 (en) * 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途

Also Published As

Publication number Publication date
ES2295026T3 (es) 2008-04-16
EP1177312A4 (de) 2004-08-25
JP4828703B2 (ja) 2011-11-30
NZ515678A (en) 2004-01-30
ZA200109270B (en) 2002-11-13
EP2357193A1 (de) 2011-08-17
JP2003527078A (ja) 2003-09-16
EP2357193B1 (de) 2015-11-04
CY1107138T1 (el) 2012-10-24
CA2367965A1 (en) 2000-11-02
CA2367965C (en) 2015-12-01
EP1177312A2 (de) 2002-02-06
DK1177312T3 (da) 2008-02-25
WO2000065027A2 (en) 2000-11-02
BR0010097A (pt) 2002-02-13
HK1118576A1 (en) 2009-02-13
MXPA01010883A (es) 2002-10-31
EP1177312B1 (de) 2007-10-31
PT1177312E (pt) 2008-01-22
DE60036937D1 (de) 2007-12-13
WO2000065027A3 (en) 2001-04-05
JP2011160804A (ja) 2011-08-25
HK1041021A1 (en) 2002-06-28
ES2530857T3 (es) 2015-03-06
DE60036937T2 (de) 2008-08-07

Similar Documents

Publication Publication Date Title
ATE377077T1 (de) Humane gil-19/ae289 proteine und dafür kodierende polynukleotide
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
ATE259243T1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
DE3856588D1 (de) Biologisch-aktive Bakterizide/permeabilitätserhöhende Proteinbruchstücke
DK0409472T3 (da) Knoglemorfogenetisk protein
NO894503D0 (no) Uretan-beskyttede aminosyre-n-karboksyanhydrider.
FI900808A0 (fi) Humant mannos bindande protein.
DE69841994D1 (de) 32 Humane sekretierte Proteine
DE69117123T2 (de) Menschliches MK Gen und Protein-Sequenz
DE69823501D1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten
DE68918673D1 (de) IgG-bindendes Protein H, kodierendes Gen dafür und Verfahren zu seiner Herstellung.
ATE126273T1 (de) Immunogenes protein und cdna-klon.
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
ATE195950T1 (de) Immunreaktive peptide des epstein-barrvirus
DK1283214T3 (da) Hidtil ukendte kollektiner
EP1220896A4 (de) NEUE HUMANE LIPASEPROTEINE, DAFüR KODIERENDE NUKLEINSäUREN UND DEREN VERWENDUNGEN
EP1897950A3 (de) Humane GIL-19/AE289-Proteine und dafür kodierende Polynukleotide
ATE329032T1 (de) Haemophilus influenza äusseres membranprotein und verwendung davon als impstoff
ATE366261T1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
SE9703137D0 (sv) Novel treatment of autoimmune diseases
FR2602586B1 (fr) Manipulateur analogique de parametres de son et de variation d'intensite lumineuse ou autres codages

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1177312

Country of ref document: EP